PubmedID,Title,Publication Date,Non-academic Author(s),Company Affiliation(s),Corresponding Author Email
40664444,Allogeneic cetuximab-armed gamma delta T cells using antibody-cell conjugation technology for the treatment of EGFR-expressing solid tumors.,2025,Hao-Kang Li; Tai-Sheng Wu; Ying Ru; Yi-Chiu Kuo; Chia-Yun Lee; Pei-Ju Leng; Yi-Chun Hsieh; Yun-Jung Chiang; Zih-Fei Cheng; Yan-Liang Lin; Shih-Chia Hsiao; Sai-Wen Tang,"Acepodia Biotech Inc, Alameda, California, USA.; Acepodia Biotech Inc, Alameda, California, USA.; Acepodia Biotech Inc, Alameda, California, USA.; Acepodia Biotech Inc, Alameda, California, USA.; Acepodia Biotech Inc, Alameda, California, USA.; Acepodia Biotech Inc, Alameda, California, USA.; Acepodia Biotech Inc, Alameda, California, USA.; Acepodia Biotech Inc, Alameda, California, USA.; Acepodia Biotech Inc, Alameda, California, USA.; Acepodia Biotech Inc, Alameda, California, USA.; Acepodia Biotech Inc, Alameda, California, USA saiwen@acepodiabio.com sonny@acepodiabio.com.; Acepodia Biotech Inc, Alameda, California, USA saiwen@acepodiabio.com sonny@acepodiabio.com.",saiwen@acepodiabio.com
40661158,High Cell Density Perfusion Process of Quail Cells Producing Oncolytic rVSV-NDV.,2025,Markus Wolschek,Nuvonis Technologies GmbH Vienna Austria.,Not found
40650023,Clinical and Transcriptomic Characterization of Metastatic Hormone-Sensitive Prostate Cancer Patients with Low PTEN Expression.,2025,Marta Garcia de Herreros; Natalia Jiménez; Joan Padrosa; Caterina Aversa; Laura Ferrer-Mileo; Samuel García-Esteve; Laia Fernández-Mañas; Mercedes Marín-Aguilera; Manuel Mazariegos; Aleix Prat; Òscar Reig; Begoña Mellado,"Translational Genomics and Targeted Therapeutics in Solid Tumors Lab, Fundació de Recerca Clínic Barcelona-Institut d'Investigacions Biomèdiques August Pi i Sunyer (FRCB-IDIBAPS), 08036 Barcelona, Spain.; Translational Genomics and Targeted Therapeutics in Solid Tumors Lab, Fundació de Recerca Clínic Barcelona-Institut d'Investigacions Biomèdiques August Pi i Sunyer (FRCB-IDIBAPS), 08036 Barcelona, Spain.; Translational Genomics and Targeted Therapeutics in Solid Tumors Lab, Fundació de Recerca Clínic Barcelona-Institut d'Investigacions Biomèdiques August Pi i Sunyer (FRCB-IDIBAPS), 08036 Barcelona, Spain.; Translational Genomics and Targeted Therapeutics in Solid Tumors Lab, Fundació de Recerca Clínic Barcelona-Institut d'Investigacions Biomèdiques August Pi i Sunyer (FRCB-IDIBAPS), 08036 Barcelona, Spain.; Translational Genomics and Targeted Therapeutics in Solid Tumors Lab, Fundació de Recerca Clínic Barcelona-Institut d'Investigacions Biomèdiques August Pi i Sunyer (FRCB-IDIBAPS), 08036 Barcelona, Spain.; Translational Genomics and Targeted Therapeutics in Solid Tumors Lab, Fundació de Recerca Clínic Barcelona-Institut d'Investigacions Biomèdiques August Pi i Sunyer (FRCB-IDIBAPS), 08036 Barcelona, Spain.; Translational Genomics and Targeted Therapeutics in Solid Tumors Lab, Fundació de Recerca Clínic Barcelona-Institut d'Investigacions Biomèdiques August Pi i Sunyer (FRCB-IDIBAPS), 08036 Barcelona, Spain.; Translational Genomics and Targeted Therapeutics in Solid Tumors Lab, Fundació de Recerca Clínic Barcelona-Institut d'Investigacions Biomèdiques August Pi i Sunyer (FRCB-IDIBAPS), 08036 Barcelona, Spain.; Translational Genomics and Targeted Therapeutics in Solid Tumors Lab, Fundació de Recerca Clínic Barcelona-Institut d'Investigacions Biomèdiques August Pi i Sunyer (FRCB-IDIBAPS), 08036 Barcelona, Spain.; Translational Genomics and Targeted Therapeutics in Solid Tumors Lab, Fundació de Recerca Clínic Barcelona-Institut d'Investigacions Biomèdiques August Pi i Sunyer (FRCB-IDIBAPS), 08036 Barcelona, Spain.; Translational Genomics and Targeted Therapeutics in Solid Tumors Lab, Fundació de Recerca Clínic Barcelona-Institut d'Investigacions Biomèdiques August Pi i Sunyer (FRCB-IDIBAPS), 08036 Barcelona, Spain.; Translational Genomics and Targeted Therapeutics in Solid Tumors Lab, Fundació de Recerca Clínic Barcelona-Institut d'Investigacions Biomèdiques August Pi i Sunyer (FRCB-IDIBAPS), 08036 Barcelona, Spain.",Not found
40645660,Pretreatment and on-treatment ctDNA and tissue biomarkers predict recurrence in patients with stage IIIB-D/IV melanoma treated with adjuvant immunotherapy: CheckMate 915.,2025,Hao Tang; Keyur Desai; Sheen Wang; Corey Ritchings; Shu-Pang Huang; Jonathan Baden; David Balli; Han Chang; Gina Fusaro; Daniel Tenney; Sonia Dolfi,"Bristol Myers Squibb, Princeton, New Jersey, USA.; Bristol Myers Squibb, Princeton, New Jersey, USA.; Bristol Myers Squibb, Princeton, New Jersey, USA.; Bristol Myers Squibb, Princeton, New Jersey, USA.; Bristol Myers Squibb, Princeton, New Jersey, USA.; Bristol Myers Squibb, Princeton, New Jersey, USA.; Bristol Myers Squibb, Princeton, New Jersey, USA.; Bristol Myers Squibb, Princeton, New Jersey, USA.; Bristol Myers Squibb, Princeton, New Jersey, USA.; Bristol Myers Squibb, Princeton, New Jersey, USA.; Bristol Myers Squibb, Princeton, New Jersey, USA Sonia.Dolfi@bms.com georgina.long@sydney.edu.au.",Sonia.Dolfi@bms.com
